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Abstract 
Backgroun / Aim. Constant production of free radicals and antioxidants (AO) in the cell is 
a part of normal cellular function. Their imbalance might take a part in pathophysiology of 
many diseases, including Parkinson’s disease (PD). Evaluation of the disease status, 
prooxidant-antioxidant balance (PAB) and antioxidants are being widely estimated. The 
aim of this study was to examine potential interaction between several AO variables (GSH, 
SOD, CAT and PAB) and clinicopathological features of patients with PD, particularly 
Hoehn and Yahr (H&Y) stage. 
Methods. A multivariate analysis of variance (MANOVA) was conducted to test the 
hypothesis of the mean differences between clinicopathological characteristics (gender, age 
at examination, duration of the disease, and H&Y stage) and AO variables, compared with 
age/sex matched healthy controls. The study included 91 patients with idiopatic PD patients 
and 20 healthy controls. Results. The multivariate effect size was estimated at 0.269, 
p <0.001, implying that 27.0% of the variance of the dependent variables was accounted for 
H&Y stage. Univariate tests showed that there were significant differences (p <0.001) 
across the H&Y stage on all AO variables. The H&Y stage remained significant predictor 
after controlling for the second variable, the disease duration (p <0.001, η2 = 0.249), and 
there were still significant differences across the H&Y stage on all variables, with effect 
size ( η2) ranging from 0.132, p =0.011 (lnGSH) to the still high values of 0.535 (lnPAB), 
0.627 (lnSOD) and 0.964 (lnCAT). 
Conclusion. The results indicate that higher level of oxidative stress in blood of PD 
patients is possibly related to PD stage. Along with reduction of SOD and GSH level, CAT 
activity was elevated in comparison to healthy subjects. Furthermore, PAB was shifted 
toward oxidative stress. 
 
Keywords: p 
parkinson disease - superoxide dismutase - catalase – glutathione - prooxidant-
antioxidant balance 
 
Apstrakt 
 
Uvod/Cilj. Ćelijska homeostaza zasniva se na konstantnoj produkciji slobodnih radikala i 
antioksidanasa (AO). Svako narušavanje njihove ravnoteže može dovesti ili uĉestvovati u 
patofiziološkim promenama mnogih bolesti, ukljuĉujući i Parkinsonovu bolest (PB). Kako 
bi se pratio status bolesti, koristi se veliki broj parametara, ukljuĉujući i prooksidativni-
antioksidativni balans (PAB) i AO, koji ujedno predstavljaju i fokus ispitivanja ove studije. 
Stoga, cilj ove studije je ispitivanje potencijalne interakcije izmeĊu AO varijabli (GSH, 
SOD, CAT i PAB) i kliniĉko-patoloških osobina PB pacijenta, najviše Hoehn i Yahr 
(H&Y) stepena bolesti. Metode. Multivarijantna analiza varijanse (MANOVA) je 
korišćena za analizu hipoteze meĊusobnih razlika izmeĊu kliniĉko-patoloških 
karakteristika (pola, starosti, dužine trajanja bolesti i H&Y stepena bolesti) i AO varijabli 
sa zdravim kontrolama. Studija je ukljuĉivala ukupno 111 ispitanika (91 pacijenata kojima 
je dijagnostifikovana idiopatska PB i 20 zdravih kontrola). Rezultati. Multivarijantni 
efekat je procenjen na 0,269, p <0,000, što implicira da se 27.0% varijanse zavisne 
varijable odnosi na H&Y stepen bolesti. Univarijantni test je pokazao da postoji statistiĉki 
znaĉajna razlika (p <0,001) kroz H&Y stepen bolesti svih AO varijabli. H&Y stepen 
bolesti je ostao znaĉajan indikator i nakon uvoĊenja druge varijable, dužine trajanja bolesti 
 4 
 
(p <0,001, η2 = 0,249). Pokazano je da je ostala znaĉajna razlika kroz H&Y stepen bolesti 
za sve varijable, tako da je jaĉina odnosa dve varijable od 0,132 (lnGSH) do i dalje visokih 
vrednosti 0,535 (lnPAB), 0,627 (lnSOD) i 0,964 (lnCAT). Zaključak. Rezultati ukazuju da 
je visoki nivo oksidativnog stresa u krvi pacijenata obolelih od PB verovatno povezan sa 
stepenom bolesti. Zajedno sa smanjenjem aktivnosti SOD i nivoa GSH, aktivnost CAT se 
povećava u poreĊenju sa zdravim kontrolama. Pored toga, PAB ukazuje na povećani 
oksidativni  stres kod pacijenata obolelih od PB.  
 
Ključne reči: 
parkinsonova bolest – superoksid dizmutaza – glutation – prooksidans-antioksidans 
balans 
 
Introduction 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease, histologically characterized by progressive loss of dopaminergic 
neurons in substantia nigra pars compacta (SNpc) and formation of Lewy bodies1. It is 
manifested by cardinal features such as bradykinesia, rigidity, tremor and postural 
instability, and good response to levodopa (L-dopa) is often used to support the diagnosis 
of PD2. Although the exact mechanism of PD pathogenesis still remains unclear, studies 
have indicated that oxidative stress (OS), inflammation, mitochondrial dysfunction and 
proteasomal inhibition are the major factors that accelerate dopaminergic 
neurodegeneration3. 
Oxidative stress is defined as an imbalance between the production of reactive 
oxygen species (ROS) and antioxidant (AO) defense capacity. ROS are generally short-
lived and highly reactive molecules derived from oxygen4, varying in their site of 
formation, physiological function, reactivity and biological half-life. They include free 
radicals, such as hydroxyl and superoxide radicals, and non-radicals including hydrogen 
peroxide (H2O2) and singlet oxygen5. Maintenance of the physiological level of ROS is 
basically regulated by antioxidant enzymes (AOE) and small antioxidant molecules6. 
Antioxidant enzymes include superoxide dismutases (SODs), catalase (CAT), 
glutathione peroxidases (GPxs), glutathione reductases (GRs) and glutathione-S-
transferases (GSTs), while non-enzymatic antioxidants are represented by glutathione 
(GSH), ascorbic acid (vitamin C), α-tocopherol (Vitamin E), flavonoids, etc.7. The main 
function of SOD is catalyzing the breakdown of highly reactive superoxide anion into 
oxygen and the less reactive H2O2, which is further decomposed to water and oxygen by 
CAT or GPx8. Disturbance of AOE activity is strongly implicated in a variety of age–
related brain disorders9. 
Glutathione is the major small AO molecule6, with the concentration of 1–3 mM in 
the brain cells10. It is highly abundant in the cytosol (1-11mM), nucleus (3-15 mM) and 
mitochondria (5-11 mM)11. In some studies, a much lower concentration of 2 μM was found 
in blood plasma10. GSH can reduce superoxide radicals, hydroxyl radicals, and 
peroxynitrites, reacting alone or with other enzymes, such as GPx or GST12.  
Other than individual molecules, one of the important parameters for oxidative 
stress evaluation is a prooxidant-antioxidant balance (PAB), which determines a state of 
dynamic balance between free radicals that are produced and those utilized (scavenged)13. 
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Similar to other diseases, a disturbed AO balance renders PD patients more 
vulnerable to OS. Thus, to further evaluate its degree, the present study investigated PAB 
and AO enzymes (SOD, CAT), as the first line of defense against ROS and GSH level in 
the blood of PD patients, compared to healthy subjects. Furthermore, the relation of AO 
parameters with clinicopathological features such as gender, age, duration of the disease, 
and Hoehn and Yahr (H&Y) staging was estimated.   
 
 
Methods  
 
Participants 
 
The study comprised 91 patients with idiopathic PD, and 20 healthy controls, 
originated in the Republic of Serbia. All blood samples were collected at the Neurology 
Clinic, Clinical Center of Serbia, University of Belgrade. The study was performed in 
compliance with the ethical principles of the Declaration of Helsinki and all applicable 
national laws and regulations. The study protocol was approved by the Ethical Committee 
of Clinical Centre of Serbia, Belgrade, and written informed consent was obtained from 
each patient prior to study engagement. All patients had idiopathic PD diagnosed in 
accordance with UK brain bank criteria14. Inclusion criteria were disease duration (up to 25 
years), age (30 – 75 years), H&Y stage (I – IV), receiving symptomatic PD therapy and a 
stable dose of L-dopa medications for longer than 3 months. Patients with current evidence 
of a recent diagnosis of malignancy marked autonomic disturbances, a renal insufficiency 
or failure, hepatitis, serious and or unstable gastrointestinal, hematologic or other medical 
disorders, as well as subjects using antipsychotics were excluded from the study. The 
clinicopathological features of patients included age, gender, disease duration and H&Y 
stage of disease (Table 1). 
 
Blood sampling and biochemical measurements 
 
Venous blood samples were collected from each patient using conventional 
techniques into Vacutainer (BD Diagnostics, Plymouth, UK) tubes with K2EDTA as an 
anticoagulant. For PAB measurement, one batch was centrifuged at 1500 g, for 10 min, at 
4oC, within 30 min of collection. Plasma was carefully separated and stored at -80oC until 
further processing. 
For enzyme activity measurements, the second batch of unfrozen blood was used. 
All blood samples were diluted with cold dH20 1:3 (v/v), vortexed and centrifuged for 
1 min (10000 g, 15 min, 4oC). Supernatants were collected and kept at -80oC till the assay. 
For GSH measurement the blood was prepared as recommended by the kit producer 
(BIOXYTECH® GSH-420TM, OXIS International Inc., Foster City, CA, USA). 
 
Assays 
Total SOD activity was measured using Superoxide Dismutase Assay Kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). The reaction between superoxide radicals (O2.-) 
and tetrazolium salt, generated by xanthine oxidase, results in the development of formazan 
dye, with max absorbance on 450nm. SOD inhibits this reaction by dismutation of O2.- and 
one unit of SOD is defined as the amount of enzyme needed to exhibit 50 % dismutation of 
 6 
 
superoxide radical. Measurements were performed in a microplate reader (Wallac 1420 
Victor2, Perkin Elmer Inc., Waltham, MA, USA). 
Total GSH concentration was determined by the BIOXYTECH® GSH-420TM Assay 
(OXIS International, Inc., Foster City, CA, USA). The measurement of total GSH 
concentration was performed in three colorimetric reaction steps. Tris (2-carboxyethyl) 
phosphine (TCEP) as a reducing agent, reduces all oxidized glutathione present in the 
sample. During the second step, chromogen (4-chloro-1-methyl-7-
trifluoromethylquinolinium methylsulfate) reacts with thiols in the sample and forms 
thioethers. Addition of base (NaOH) raises reaction mixture pH over 13 and chromophoric 
thione is formed as a result of β–elimination specific to the GSH-thioether. GSH 
concentration is directly proportional to the absorbance at 420 nm. 
Catalase activity measurement was performed according to the method by Beutler15. 
The reaction mixture was prepared from 50 µl of a Tris-HCl buffer (1 M Tris-HCl, 5 mM 
EDTA, pH 8.0), 900 µl of a substrate (10 mM H2O2), 30 µl of dH20, and 20 µl of the 
sample. Decomposition of H2O2 was monitored spectrophotometrically (UV Line 9400, SI 
Analytics GmbH, Mainz, Germany) at 230 nm, 3 min at 37ºC. One unit of CAT activity is 
defined as the amount of enzyme which degrades 1 μmol of H2O2 per min under the assay 
conditions. The extinction coefficient for H2O2 is 0.071 mM-1cm-1. 
 
Prooxidant-antioxidant balance 
 
Evaluation of PAB was performed as described previously16. Following the 
incubation for 2 min at room temperature in dark, 200 μl of working solution (1 ml TMB 
cation solution with 10 ml TMB solution) was added to a 96-well microtiter plate and 
mixed with 10 μl of plasma sample, standard or blank (dH2O). The mixture was incubated 
in a dark place for 12 min, at 37°C and the reaction was stopped by adding 100 μl of 2 N 
HCl. The values of PAB in plasma samples were determined at 450 nm, with a reference 
wavelength of 620 or 570 nm, by comparing optical density (OD) of a sample to the 
standard curve. PAB values are expressed in arbitrary units (HK). 
 
Statistical analysis 
 
The statistical analyses were performed by the GraphPad Prism and SPSS 18.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± SD. General linear 
model (GLM) was used to test the differences between AO and clinicopathological 
variables, followed by Dunnett and Scheffe post hoc tests. Since examined variables had 
not passed the normality of the distribution (Shapiro-Wilks test), data were previously log-
transformed. Pearson correlation analysis was performed to test the correlation between 
AO/clinicopathological variables. The p-value < 0.05 was considered statistically 
significant. 
 
Results 
 
The average age of healthy controls was 57.5 ± 8.5 years, and for PD patients it was 
62.7 ± 9.7 years, with a predominance of males (65.9 %). The H&Y stage 1 was the least 
one represented (9.9%), (Table 1). The activity of AO enzymes (SOD, CAT), the GSH 
level and PAB are shown in Figure 1. 
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A multivariate analysis of variance (MANOVA) was conducted to test the 
hypothesis of the mean differences between the H&Y stage and AO variables.Prior to 
conducting the analysis, the Pearson correlation was performed between the dependent 
variables in order to test the correlation assumption (Table 2) and significant pattern of 
correlations was observed amongst all of the dependent variables. Since the Box’s M value 
of 110.06 (p<0.001) indicated significant difference between the covariance matrices, the 
Pillais’ Trace test was used. The MANOVA effect (Pillais’ Trace = 1.07, 
F = 9.103, p < 0.001), showed significant differences among the H&Y stage groups on the 
linear combination of the dependent variables. The multivariate effect size was estimated at 
0.269, implying that 27.0 % of the variance of the examined AO parameters was accounted 
for the H&Y stage. 
The homogeneity of variance assumption was tested for the AO variables and two 
(lnGSH and lnPAB) of the four Levene’s F tests were statistically significant (p < 0.05). 
Prior to conducting a series of follow-up ANOVAs, the Bonferroni procedure was used to 
protect against Type I error, adjusting the alpha level to p < 0.001. Univariate tests showed 
that there were significant differences (p < 0.001) across the H&Y stage on all AO 
variables, with effect size (η2) ranging from 0.365 (lnGSH) to the extremely high values of 
0.744 (lnPAB), 0.861 (lnSOD) and 0.988 (lnCAT) (Table 3a). 
Finally, the series of post-hoc analyses (Dunnett and Scheffe test) were performed to 
examine individual mean difference comparisons across all H&Y stage and all four AO 
variables. The results revealed that high effect size observed by univariate analysis is the 
consequence of the mean differences in AO values between H&Y stage and control values 
(Dunnett test, p < 0.001). Scheffe test did not reveal a significant mean difference in AO 
values between any of H&Y stage.  
In the next step, to test whether H&Y stageremains significant after controlling for 
the next clinical variable, the disease duration was added as a covariate to the model.  The 
MANCOVA analysis of the effect of the H&Y stage on all AO parameters was still 
significant (Pillais’ Trace = 0.998, F = 7.560, p <0.000), η2 0.249. Univariate tests showed 
that there were still significant differences across the H&Y stage on all AO variables, with 
effect size (η2) ranging from 0.132, p = 0.011 (lnGSH) to the still high values of 0.535 
(lnPAB), 0.627 (lnSOD) and 0.964 (lnCAT) (Table 3b). 
There was no significant association between AO parameters and gender (Pillais’ 
Trace = 0.033, F = 0.713,p =0 .585, η2 = 0.033) or age (Pillais’ Trace = 0.70,F = 1.558, 
p =0 .193, η2 = 0.070). 
 
Discussion 
Oxidative stress has long been implicated in pathophysiological mechanisms 
underlying various neurodegenerative diseases, including PD. Investigation of 
different oxidant/AO parameters have yielded inconsistent results and it is still challenging 
to assess these parametersin peripheral blood of patients with PD. The current study is 
focused on the association of specific AO variables (GSH, SOD, CAT, and PAB) and 
clinicopathological features of patients with PD, particularly H&Y stage. 
Among all ROS-scavenging enzymes, SOD is often regarded as the first line of 
defense and there is sufficient evidence relating superoxide anion to human diseases, such 
as PD17. The results of our study have shown decreased SOD activities in PD patients 
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compared to healthy subjects, which is in accordance with the findings of some authors18-21 
while the others22-25reported increased SOD activity or no significant change at all26,27. It is 
known that AO enzymes are regulated through the AO system to cope with acute or mild 
OS; however, severe or prolonged OS may induce consumption and decrease of enzyme 
activity. The decrease of SOD observed in our study might involve inactivation of SOD by 
ROS or some posttranslational modifications28.This observation is comparable with the fact 
that reduced activity of blood SOD is detected in many chronic diseases such as obstructive 
pulmonary disease29, renal failure30, as well as in some neurological disorders31. Chronic OS 
has already been speculated to cause antioxidant consumption and thus a decline in 
antioxidant levels32. Another possible reason for decreased SOD level could be in mutations 
that not only provoke a decline in its activity but also induce self-aggregation of mutated 
SOD proteins - an initial cause of neuron malfunction leading to disease, as already shown 
in a cell culture model of amyotrophic lateral sclerosis33. The confirmation of such 
assumptions requires more extensive research in the field of molecular events related to this 
disease. 
The term OS describes the condition where free radicals production exceeds a 
capacity of AO system. Studies indicated different findings of erythrocyte CAT activity in 
PD patients in which no significant changes27,34 or deficit18,21 of CAT were recorded in 
comparison with healthy subjects. PD patients involved in the present study had elevated 
CAT activity compared to healthy controls, and there were no differences between H&Y 
stages and disease duration. Similar results were obtained in the research of Younes-
Mhenniet et al.22, who have not observed the correlation between the duration of illness and 
CAT activity. 
Several studies have shown contrasting results; Sudha et al.35 observed no 
significant changes of erythrocyte antioxidants in PD patients while Abraham and 
coworkers21 reported decreased AO enzymes activity in PD patients compared to controls. 
Considering that CAT is crucial in removing H2O2 at higher concentrations36 (GPx are 
predominant at physiologically low levels of H2O237), elevation of CAT activity in the blood 
of PD patients confirms the general conclusion of this study that PD patients are exposed to 
chronic oxidative stress38. 
It is hypothesized that the adjustment of the AO system is based on shifts in AO 
activities rather than on the formation of new AO resources. Thus, for some aspects of the 
issue, it may be more useful to study whole groups of radical scavengers rather than 
focusing on individual molecule species39. PAB can be considered as a measure of an 
imbalance between oxidants (H2O2, tert-butylhydroperoxide, chloramine T and HClO) and 
antioxidants (vitamin C, trolox, GSH, uric acid, bilirubin, albumin, and ceruloplasmin)40. In 
our study, PAB has shifted forward the OS, indicating that PD patients had an elevated 
level of OS compared with healthy subjects, regardless of the H&Y stage. 
The physiological roles played by the GSH include maintenance of thiol redox 
potential, clearing metabolic waste, and as a reservoir for amino acids41. Since GSH is 
involved in antioxidant defense, and regulation of cellular metabolic functions ranging 
from gene expression, DNA, and protein synthesis to signal transduction, cell proliferation 
and apoptosis42, its depletion might have a wide impact on many physiological and 
pathological processes. For instance, GSH deficiency has long been implicated in PD 
degeneration43. A recent report even suggests that whole blood GSH may have the utility as 
a biomarker in PD progression as it was statistically associated with PD status44. 
Accordingly, in our study, a blood concentration of GSH in PD patients was significantly 
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decreased compared to healthy controls, and such tendency was more pronounced through 
H&Y stages. These findings are important as the changes in the level of GSH have 
consequences to numerous molecular processes as well as the progression of the disease. 
Furthermore, it should be emphasized that the exact cause of GSH reduction has not been 
fully clarified, however, it is known that the most common ways for reducing GSH involve 
its consumption by GPx, conjugation reaction with proteins45 and 4-hydroxynonenal (4-
HNE)46 and translocation of GSH/GSSG across the plasma membrane47. In order to 
compensate for this decrease, the possible ways of therapeutic compensation of GSH 
treatments are investigated. They include intranasal48, intravenous, and liposomal49 GSH 
augmentation, and some of them showed a promising effect in the treatment of PD 
disease50. 
 
Conclusions 
 
Obtained results show that some of the examined AO parameters in blood of PD patients 
are possibly related to PD stage. We observed a correlation of H&Y stage with PAB and 
AO parameters. The reduction of GSH level was related with higher H&Y stage while 
PAB, SOD and CAT activity changed regardless of the H&Y score. 
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Fig. 1 ‒ Superoxide dismutase (SOD) and catalase (CAT) activity, glutathione concentration (GSH), 
and prooxidant-antioxidant balance (PAB) in blood of healthy controls (C) and different H&Y score of 
patients with Parkinson disease. Boxes represent values between 25
th
 and 75
th
 percentiles. Medians are 
given inside the boxes. Whiskers extend between min and max values. 
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Table 1 
Demographic and clinical data of patients with PD 
Characteristic     N (%) 
Gender    
Male   60 (65.9) 
Female   31 (34.1) 
Age at examination (years)   62.7±9.7# 
<59   28 (30.8) 
59-70   44 (48.3) 
>70   19 (20.9) 
Age at disease onset (years)   53.8±9.1# 
Disease duration (years)   8.8±6.2# 
<3   18 (19.8) 
3-8   35 (38.5) 
>8   38 (41.8) 
H & Y stage    
1   9 (9.9) 
2   31 (34.1) 
3   27 (29.7) 
4   24 (26.4) 
  N -number of patients; (%)-fractions in relation to N; 
#-Mean values ± SD 
 
 
 
Table 2. 
 Pearson correlation between AO parameters 
Correlations 
 
lnGSH lnSOD lnCAT lnPAB 
lnGSH Pearson Correlation 1 -0.498** 0.581** 0.595** 
Sig. (2-tailed)  0.000 0.000 0.000 
N 111 111 111 111 
lnSOD Pearson Correlation  1 -0.922** -0.793** 
Sig. (2-tailed)   0.000 0.000 
N  111 111 111 
lnCAT Pearson Correlation   1 0.864** 
Sig. (2-tailed)    0.000 
N   111 111 
**. Correlation is significant at the 0.01 level (2-tailed) 
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Table 3. 
GLM analysis of the associations between a) H&Y stage and AO parameters; b) H&Y 
stage and AO parameters after controlling for disease duration 
    lnGSH lnSOD lnCAT lnPAB 
a      
H&Y F 3.462 38.268 607.374 26.187 
 p 0.011 p<0.001 p<0.001 p<0.001 
 eta2 13.2% 62.7% 96.4% 53.5% 
b      
Disease F 0.042 3.523 0.650 0.790 
duration p 0.837 0.064 0.422 0.377 
  eta2 0.000 3.7% 0.7% 0.9% 
GSH – glutathione, SOD – superoxide dismutase, CAT – catalase, PAB – prooxidant/antioxidant 
balance, eta – quantified variance components, p – value indicates statistical significance 
 
 
 
 
‒                                                                                                    Received on July 18, 2018. 
Revised on August 9, 2018. 
                                                                                            Accepted on September 11, 2018. 
                                                                                        Online First September, 2018. 
 
 
 
 
